Clinical Trial

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Study acronym: CLOVER-WaM

Active, Not Recruiting Phase 2

Record status

This record was last updated March 18, 2026 (before its estimated June 22, 2026 completion). Its status may not reflect the trial's current state.

Summary

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Protocol Amendment History 29 amendments

This ClinicalTrials.gov record has been amended 29 times since 2016-11-01; most recent amendment 2026-03-16.

Status change: Recruiting → Active, Not Recruiting 2024-09-10

Status change: Active, Not Recruiting → Recruiting 2024-06-04

Status change: Recruiting → Active, Not Recruiting 2024-06-03

Status change: Active, Not Recruiting → Recruiting 2024-01-19

Status change: Recruiting → Active, Not Recruiting 2024-01-12

Status change: Not Yet Recruiting → Recruiting 2017-07-17

Trial Details

NCT Number	NCT02952508
Lead Sponsor	Cellectar Biosciences, Inc.
Conditions	Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma +1 more
Enrollment	120 participants
Start Date	2017-07-26
Primary Completion	2026-06-22 (estimated)
Study Completion	2027-12-22 (estimated)
Updated on ClinicalTrials.gov	2026-03-18